Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms

被引:2
|
作者
Neculae, Gabriela [1 ,2 ]
Adam, Robert [1 ,2 ]
Jercan, Andreea [2 ,3 ]
Badelita, Sorina [3 ]
Tjahjadi, Catherina [4 ]
Draghici, Mirela [5 ]
Stan, Claudiu [6 ]
Bax, Jeroen J. [4 ]
Popescu, Bogdan A. [1 ,2 ]
Marsan, Nina Ajmone [4 ]
Coriu, Daniel [2 ,3 ]
Jurcut, Ruxandra [7 ,8 ]
机构
[1] Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Expert Ctr Rare Cardiovasc Dis, Bucharest, Romania
[2] Carol Davila Univ Med & Pharm, Bucharest, Romania
[3] Fundeni Clin Inst, Dept Hematol, Bucharest, Romania
[4] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
[5] Fundeni Clin Inst, Dept Neurol, Bucharest, Romania
[6] Fundeni Clin Inst, Dept Nucl Med, Bucharest, Romania
[7] Carol Davila Univ Med & Pharm, Expert Ctr Rare Cardiovasc Dis, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
[8] Carol Davila Univ Med & Pharm, Euroecholab, Prof Dr CC Iliescu Emergency Inst Cardiovasc Dis, Bucharest, Romania
来源
ESC HEART FAILURE | 2024年 / 11卷 / 05期
关键词
AL amyloidosis; ATTR amyloidosis; Cardiac amyloidosis; Diagnostic score; Myocardial deformation; CONSENSUS DOCUMENT; AL AMYLOIDOSIS; DIAGNOSIS; ECHOCARDIOGRAPHY; STANDARDIZATION; DYSFUNCTION; BIOMARKERS; PROGNOSIS;
D O I
10.1002/ehf2.14852
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Systemic amyloidosis represents a heterogeneous group of diseases resulting from amyloid fibre deposition. The purpose of this study is to establish a differential diagnosis algorithm targeted towards the two most frequent subtypes of CA. Methods and results We prospectively included all consecutive patients with ATTR and AL evaluated between 2018 and 2022 in two centres in a score derivation cohort and a different validation sample. All patients had a complete clinical, biomarker, electrocardiographic, and imaging evaluation. Confirmation of the final diagnosis with amyloid typing was performed according to the current international recommendations. The study population included 81 patients divided into two groups: ATTR (group 1, n = 32: 28 variant and 4 wild type) and AL (group 2, n = 49). ATTR patients were younger (50.7 +/- 13.9 vs. 60.2 +/- 7.3 years, P = 0.0001), and significantly different in terms of NT-proBNP [ATTR: 1472.5 ng/L (97-4218.5) vs. AL 8024 ng/L (3058-14 069) P = 0.001], hs-cTn I [ATTR: 10 ng/L (4-20) vs. AL 78 ng/L (32-240), P = 0.0002], GFR [ATTR 95.4 mL/min (73.8-105.3) vs. AL: 68.4 mL/min (47.8-87.4) P = 0.003]. At similar left ventricular (LV) wall thickness and ejection fraction, the ATTR group had less frequently pericardial effusion (ATTR: 15% vs. AL: 33% P = 0.0027), better LV global longitudinal strain (ATTR: -13.1% +/- 3.5 vs. AL: -9.1% +/- 4.3 P = 0.04), RV strain (ATTR: -21.9% +/- 6.2 vs. AL: -16.8% +/- 6 P = 0.03) and better reservoir function of the LA strain (ATTR: 22% +/- 12 vs. AL: 13.6% +/- 7.8 P = 0.02). Cut-off points were calculated based on the Youden method. We attributed to 2 points for parameters having an AUC > 0.75 (NT-proBNP AUC 0.799; hs-cTnI AUC 0.87) and 1 point for GFR (AUC 0.749) and TTE parameters (GLS AUC 0.666; RV FWS AUC 0.649, LASr AUC 0.643). A score of equal or more than 4 points has been able to differentiate between AL and ATTR (sensitivity 80%, specificity 62%, AUC = 0.798). The differential diagnosis score system was applied to the validation cohort of 52 CA patients showing a sensitivity of 81% with specificity of 77%. Conclusions CA is a complex entity and requires extensive testing for a positive diagnosis. This study highlights a series of non-invasive checkpoints, which can be useful in guiding the decision-making process towards a more accurate and rapid differential diagnosis.
引用
收藏
页码:2481 / +
页数:977
相关论文
共 50 条
  • [1] Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms
    Neculae, G.
    Adam, R.
    Jercan, A.
    Badelita, S.
    Draghici, M.
    Stan, C.
    Rosca, M.
    Beladan, C.
    Coriu, D.
    Popescu, B. A.
    Jurcut, R.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1788 - 1788
  • [2] Concurrent Transthyretin Cardiac Amyloidosis and Light Chain Amyloidosis of the Foregut
    Tan, Bryan E-Xin
    Thakkar, Samarthkumar
    Parikh, Vishal
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S100 - S100
  • [3] Transthyretin Cardiac Amyloidosis Disguised as Light Chain Amyloidosis or Multiple Myeloma?
    Stein, Andrew P.
    Matthia, Eldon L.
    Petty, Stephen A.
    Stewart, Brian
    Vilaro, Juan R.
    Al -Ani, Mohammad A. Z.
    Ahmed, Mustafa M.
    Aranda, Juan M.
    Hiemenz, John W.
    Parker, Alex M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 210 : 85 - 92
  • [4] TRANSTHYRETIN CARDIAC AMYLOIDOSIS DISGUISED AS LIGHT CHAIN AMYLOIDOSIS, OR MULTIPLE MYELOMA?
    Stein, Andrew
    Matthia, Eldon
    Petty, Stephen
    Hiemenz, John
    Parker, Alex Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 3535 - 3535
  • [5] Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients
    Versteylen, Mathijs O.
    Brons, Maaike
    Teske, Arco J.
    Oerlemans, Marish I. F. J.
    BIOMEDICINES, 2022, 10 (08)
  • [6] Differences in circulating cardiac biomarkers between immunoglobulin light-chain and transthyretin cardiac amyloidosis
    Castiglione, Vincenzo
    Aimo, Alberto
    Ghionzoli, Nicolo
    Prontera, Concetta
    Masotti, Silvia
    Musetti, Veronica
    Chubuchny, Vlad
    Spini, Valentina
    Genovesi, Dario
    Barison, Andrea
    Passino, Claudio
    Emdin, Michele
    Vergaro, Giuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0J) : J177 - J178
  • [7] Differences in circulating cardiac biomarkers between immunoglobulin light-chain and transthyretin cardiac amyloidosis
    Castiglione, V.
    Aimo, A.
    Ghionzoli, N.
    Prontera, C.
    Masotti, S.
    Grigoratos, C.
    Genovesi, D.
    Barison, A.
    Todiere, G.
    Aquaro, G. D.
    Passino, C.
    Emdin, M.
    Vergaro, G.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 362 - 362
  • [8] Clinical characteristics of patients with cardiac amyloidosis in Sarawak: Comparison between transthyretin and light-chain amyloid cardiomyopathy
    Chung, B. K.
    Leong, T. S.
    Chew, L. P.
    Law, W. C.
    Thien, L. K.
    Pang, I. X.
    Ling, H. S.
    Chow, H. B.
    Tan, C. T.
    Koh, K. T.
    Cham, Y. L.
    Said, A.
    Fong, A. Y. Y.
    Ong, T. K.
    Oon, Y. Y.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 369 : 20 - 20
  • [9] LIGHT CHAIN AND TRANSTHYRETIN CARDIAC AMYLOIDOSIS ARE MORPHOLOGICALLY AND HEMODYNAMICALLY DISTINCT
    Ye, Fan
    Amjad, Aysha
    Winsor, Scott
    Pu, Min
    Jao, Geoffrey T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 374 - 374
  • [10] PERIVASCULAR AMYLOIDOSIS DEPOSITION FOR THE DIFFERENTIATION OF IMMUNOGLOBULIN LIGHT CHAIN AND TRANSTHYRETIN CARDIAC AMYLOIDOSIS
    Medina, Frank
    Kwon, Jung Woo
    Desai, Chandni
    Mueller, Jeffrey
    Sarswat, Nitasha
    Patel, Hena
    Husain, Aliya
    Slivnick, Jeremy
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 639 - 639